AstraZeneca and Daiichi Sankyo’s Enhertu Improves PFS in First-Line HER2-Mutant Advanced NSCLC in Phase III DESTINY-Lung04
International Urology Cancer Summit and OncoDaily Announce Strategic Partnership
Using Lung Function Data to Refine Pulmonary Toxicity Risk Before Thoracic Radiotherapy
DESTINY-Lung04: Enhertu Improves First-Line PFS in HER2-Mutant NSCLC
AstraZeneca Discontinues Phase III eVOLVE-Lung02 Trial of Volrustomig Plus Chemotherapy in Metastatic NSCLC
Evelyn H. Lauder at 90: A Legacy That Transformed Breast Cancer Research
10 Must-Read Posts In GU Oncology This Week
Vivek Subbiah: Rethinking the Unified Cancer of Unknown Primary Concept
